MedTrace Logo

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

NCT04376866 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2021-07-20

No results posted yet for this study

Summary

This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

Conditions

  • Recurrent Nasopharyngeal Carcinoma

Interventions

DRUG

Toripalimab

anti-PD-1 antibody

Sponsors & Collaborators

  • Cancer Hospital of Guangxi Medical University

    lead OTHER

Principal Investigators

  • Song Qu, PhD · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-28
Primary Completion
2023-04-30
Completion
2028-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04376866 on ClinicalTrials.gov